Literature DB >> 22659540

Expression and isotopic labelling of the potassium channel blocker ShK toxin as a thioredoxin fusion protein in bacteria.

Shih Chieh Chang1, Charles A Galea, Eleanor W W Leung, Rajeev B Tajhya, Christine Beeton, Michael W Pennington, Raymond S Norton.   

Abstract

The polypeptide toxin ShK is a potent blocker of Kv1.3 potassium channels, which play a crucial role in the activation of human effector memory T-cells (T(EM)). Selective blockers constitute valuable therapeutic leads for the treatment of autoimmune diseases mediated by T(EM) cells, such as multiple sclerosis, rheumatoid arthritis, and type-1 diabetes. We have established a recombinant peptide expression system in order to generate isotopically-labelled ShK and various ShK analogues for in-depth biophysical and pharmacological studies. ShK was expressed as a thioredoxin fusion protein in Escherichia coli BL21 (DE3) cells and purified initially by Ni²⁺ iminodiacetic acid affinity chromatography. The fusion protein was cleaved with enterokinase and purified to homogeneity by reverse-phase HPLC. NMR spectra of ¹⁵N-labelled ShK were similar to those reported previously for the unlabelled synthetic peptide, confirming that recombinant ShK was correctly folded. Recombinant ShK blocked Kv1.3 channels with a K(d) of 25 pM and inhibited the proliferation of human and rat T lymphocytes with a preference for T(EM) cells, with similar potency to synthetic ShK in all assays. This expression system also enables the efficient production of ¹⁵N-labelled ShK for NMR studies of peptide dynamics and of the interaction of ShK with Kv1.3 channels.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22659540      PMCID: PMC3411878          DOI: 10.1016/j.toxicon.2012.05.017

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  43 in total

1.  Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.

Authors:  C Beeton; H Wulff; J Barbaria; O Clot-Faybesse; M Pennington; D Bernard; M D Cahalan; K G Chandy; E Béraud
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

2.  Cloning and expression of wild-type and mutant forms of the cardiotonic polypeptide anthopleurin B.

Authors:  M J Gallagher; K M Blumenthal
Journal:  J Biol Chem       Date:  1992-07-15       Impact factor: 5.157

3.  The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.

Authors:  Heike Wulff; Peter A Calabresi; Rameeza Allie; Sung Yun; Michael Pennington; Christine Beeton; K George Chandy
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

4.  BgK, a disulfide-containing sea anemone toxin blocking K+ channels, can be produced in Escherichia coli cytoplasm as a functional tagged protein.

Authors:  Sandrine Braud; Pascal Belin; Janie Dassa; Liliana Pardo; Gilles Mourier; Antony Caruana; Birgit T Priest; Paula Dulski; Maria L Garcia; André Ménez; Jean-Claude Boulain; Sylvaine Gasparini
Journal:  Protein Expr Purif       Date:  2004-11       Impact factor: 1.650

Review 5.  Potassium channels as therapeutic targets for autoimmune disorders.

Authors:  Heike Wulff; Christine Beeton; K George Chandy
Journal:  Curr Opin Drug Discov Devel       Date:  2003-09

6.  Selective blockers of voltage-gated K+ channels depolarize human T lymphocytes: mechanism of the antiproliferative effect of charybdotoxin.

Authors:  R J Leonard; M L Garcia; R S Slaughter; J P Reuben
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

7.  Mutating a critical lysine in ShK toxin alters its binding configuration in the pore-vestibule region of the voltage-gated potassium channel, Kv1.3.

Authors:  Mark D Lanigan; Katalin Kalman; Yann Lefievre; Michael W Pennington; K George Chandy; Raymond S Norton
Journal:  Biochemistry       Date:  2002-10-08       Impact factor: 3.162

8.  C-terminal domain of insulin-like growth factor (IGF) binding protein 6: conformational exchange and its correlation with IGF-II binding.

Authors:  Shenggen Yao; Stephen J Headey; David W Keizer; Leon A Bach; Raymond S Norton
Journal:  Biochemistry       Date:  2004-09-07       Impact factor: 3.162

9.  Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions.

Authors:  M Piotto; V Saudek; V Sklenár
Journal:  J Biomol NMR       Date:  1992-11       Impact factor: 2.835

10.  Charybdotoxin inhibits proliferation and interleukin 2 production in human peripheral blood lymphocytes.

Authors:  M Price; S C Lee; C Deutsch
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

View more
  13 in total

1.  Conformational flexibility in the binding surface of the potassium channel blocker ShK.

Authors:  Inbal Sher; Shih Chieh Chang; Ying Li; Sandeep Chhabra; Arthur G Palmer; Raymond S Norton; Jordan H Chill
Journal:  Chembiochem       Date:  2014-09-18       Impact factor: 3.164

2.  N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.

Authors:  Shih C Chang; Redwan Huq; Sandeep Chhabra; Christine Beeton; Michael W Pennington; Brian J Smith; Raymond S Norton
Journal:  FEBS J       Date:  2015-04-23       Impact factor: 5.542

3.  Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog.

Authors:  Mark R Tanner; Rajeev B Tajhya; Redwan Huq; Elizabeth J Gehrmann; Kathia E Rodarte; Mustafa A Atik; Raymond S Norton; Michael W Pennington; Christine Beeton
Journal:  Clin Immunol       Date:  2017-04-04       Impact factor: 3.969

4.  A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3.

Authors:  Michael W Pennington; M Harunur Rashid; Rajeev B Tajhya; Christine Beeton; Serdar Kuyucak; Raymond S Norton
Journal:  FEBS Lett       Date:  2012-10-09       Impact factor: 4.124

5.  Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma.

Authors:  Shyny Koshy; Redwan Huq; Mark R Tanner; Mustafa A Atik; Paul C Porter; Fatima S Khan; Michael W Pennington; Nicola A Hanania; David B Corry; Christine Beeton
Journal:  J Biol Chem       Date:  2014-03-18       Impact factor: 5.157

Review 6.  Differences in ion channel phenotype and function between humans and animal models.

Authors:  Mark R Tanner; Christine Beeton
Journal:  Front Biosci (Landmark Ed)       Date:  2018-01-01

7.  Genomic Structure of Two Kv1.3 Channel Blockers from Scorpion Mesobuthus eupeus and Sea Anemone Stichodactyla haddoni and Construction of their Chimeric Peptide as a Novel Blocker.

Authors:  Maryam Asadi; Hoda Ayat; Ali Mohammad Ahadi; Mohammad Sharif Ranjbar
Journal:  Biochem Genet       Date:  2021-07-20       Impact factor: 1.890

8.  A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases.

Authors:  M Harunur Rashid; Redwan Huq; Mark R Tanner; Sandeep Chhabra; Keith K Khoo; Rosendo Estrada; Vikas Dhawan; Satendra Chauhan; Michael W Pennington; Christine Beeton; Serdar Kuyucak; Raymond S Norton
Journal:  Sci Rep       Date:  2014-03-28       Impact factor: 4.379

9.  Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes.

Authors:  Shyny Koshy; Danli Wu; Xueyou Hu; Rajeev B Tajhya; Redwan Huq; Fatima S Khan; Michael W Pennington; Heike Wulff; Patricia Yotnda; Christine Beeton
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

10.  A potent and selective peptide blocker of the Kv1.3 channel: prediction from free-energy simulations and experimental confirmation.

Authors:  M Harunur Rashid; Germano Heinzelmann; Redwan Huq; Rajeev B Tajhya; Shih Chieh Chang; Sandeep Chhabra; Michael W Pennington; Christine Beeton; Raymond S Norton; Serdar Kuyucak
Journal:  PLoS One       Date:  2013-11-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.